索尼尔治疗公司完成1800万美元A轮融资，推进胰腺癌突破性HIFU疗法，扩大美国临床开发-动脉网

Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development

CISION 等信源发布 2026-04-15 20:09



可切换为仅中文







Led by Santé, the funding will support completion of the world's first randomized HIFU trial for pancreatic cancer, and accelerate U.S. clinical programs for the company's anesthesia-free, outpatient sonic therapy

由Santé领投，这笔资金将用于支持完成全球首个针对胰腺癌的随机HIFU试验，并加速该公司无需麻醉、门诊即可进行的声波治疗在美国的临床项目。

PALO ALTO, Calif.

加利福尼亚州帕洛阿尔托

，

April 15, 2026

2026年4月15日

/PRNewswire/ --

Sonire Therapeutics

索尼尔治疗学

, a U.S. based clinical-stage medical device company, today announced $18M in Series A financing. The round was led by

，一家美国临床阶段的医疗器械公司，今天宣布获得了1800万美元的A轮融资。本轮融资由

Santé Ventures

健康风险投资

with participation from Fast Track Initiative (FTI), Nomura SPARX Investment (Japan Growth Capital Investment Corporation), and SBI Investment, as well as other Japanese investors. The proceeds will accelerate clinical development, support U.S. regulatory progress following the company's 2024 FDA Breakthrough Device Designation, and advance global commercialization efforts for its innovative non-invasive cancer treatment..

参与方包括快速通道倡议（FTI）、野村SPARX投资（日本成长资本投资公司）、SBI投资，以及其他日本投资者。所得资金将加速临床开发，支持公司在2024年获得FDA突破性设备认定后的美国监管进展，并推动其创新的非侵入性癌症治疗技术的全球商业化进程。

Sonire's proprietary High-Intensity Focused Ultrasound (HIFU) therapy system combines real-time imaging guidance with patented technologies, including a noise-cancellation system, cavitation bubble visualization, and a robot-assisted positioning platform, along with advanced capabilities such as rapid multi-focus scanning, to enable precise, effective thermal ablation of tumors.

索尼尔公司专有的高强度聚焦超声 (HIFU) 治疗系统结合了实时成像引导和专利技术，包括降噪系统、空化气泡可视化以及机器人辅助定位平台，并具备快速多焦点扫描等先进功能，能够实现对肿瘤的精准、有效热消融。

Unlike conventional ultrasound-guided HIFU systems, Sonire's solution provides clear real-time visualization of the treatment site, requires no anesthesia, and can be performed on an outpatient basis in approximately 20 minutes. Additionally, this system requires only one physician to administer treatment, which lowers the cost and staff burden for hospitals..

与传统的超声引导HIFU系统不同，Sonire的解决方案能够清晰实时显示治疗部位，无需麻醉，并且大约20分钟即可在门诊完成。此外，该系统只需一名医生即可进行治疗，降低了医院的成本和人员负担。

'We are grateful for the strong support from our investors, which validates the transformative potential of our sonic technology,' said Tohru Satoh, President and CEO of Sonire Therapeutics. 'This funding enables us to complete our landmark SUNRISE-I randomized controlled trial in Japan, which will be the world's first of its kind for HIFU in pancreatic cancer, while preparing for U.S.

“我们感谢投资者的大力支持，这验证了我们的声波技术具有变革性的潜力，”Sonire Therapeutics总裁兼首席执行官Tohru Satoh表示。“这笔资金使我们能够完成在日本的里程碑式SUNRISE-I随机对照试验，这将是全球首个针对胰腺癌HIFU技术的试验，同时为进入美国做好准备。”

clinical and regulatory milestones. Our goal is to deliver a new standard of care that gives patients more time and better quality of life, without the burdens of invasive procedures or anesthesia.'.

临床和监管里程碑。我们的目标是提供一种新的护理标准，使患者获得更长的生存时间和更好的生活质量，同时无需承受侵入性手术或麻醉的负担。

Pancreatic cancer remains one of the most lethal diseases, with a 5-year survival rate of only 12%. Existing treatments are limited, and to date, there is the still high unmet medical needs due to a lack of established standard local therapy options. Sonire's approach is designed to prolong overall survival when combined with chemotherapy while offering a safer, more patient-friendly alternative to surgery or radiation..

胰腺癌仍然是最致命的疾病之一，5年生存率仅为12%。现有治疗方法有限，迄今为止，由于缺乏成熟的局部治疗标准方案，医疗需求仍未得到满足。Sonire的方法旨在与化疗结合使用时延长总体生存期，同时提供一种比手术或放疗更安全、对患者更友好的替代方案。

Foundational work from an academic-led study using a prototype HIFU system (MoonShot-2) demonstrated a 66% disease control rate in patients with advanced or refractory pancreatic and biliary tract cancers in a sonodynamic therapy (SDT) setting. These findings have informed the development of Sonire's current system. The SUNRISE-I study (HIFU with chemotherapy vs.

学术主导的研究使用原型高强度聚焦超声系统（MoonShot-2）进行的基础工作表明，在声动力治疗（SDT）环境下，晚期或难治性胰腺和胆道癌症患者的疾病控制率达到66%。这些发现为Sonire当前系统的开发提供了依据。SUNRISE-I研究（高强度聚焦超声联合化疗 vs.

chemotherapy alone) is ongoing across seven leading Japanese hospitals with Sonire's current system. The company holds 25 issued patents and 22 pending..

仅化疗）正在日本七大领先医院使用Sonire的现有系统进行中。该公司拥有25项已颁发的专利和22项待审批的专利。

'Sonire has engineered a genuine leap forward in next generation HIFU by solving the core challenges of visualization, precision, and workflow that so far have limited the field,' noted Dennis McWilliams, Managing Director for Santé. 'Santé is excited to lead this round to expand Sonire's corporate footprint to the United States and build upon their solid clinical foundation in Japan.'.

“Sonire通过解决可视化、精确性和工作流程等核心挑战，实现了在下一代HIFU领域的真正飞跃，这些挑战迄今为止一直限制着该领域的发展，”Santé董事总经理Dennis McWilliams指出。“Santé很兴奋能够引领这一轮投资，将Sonire的企业版图扩展到美国，并在其日本坚实的临床基础上进一步发展。”

'Sonire's differentiated approach is well positioned to bring meaningful benefit to patients globally. We look forward to continuing our support of the team as they advance U.S. clinical development' noted Koji Yasuda, Principal at Fast Track Initiative (FTI)

“Sonire的差异化方法非常有优势，能够为全球患者带来有意义的益处。我们期待继续支持该团队推进美国临床开发。” Fast Track Initiative（FTI）的负责人Koji Yasuda指出。

About Sonire Therapeutics

关于索尼尔治疗学

Sonire Therapeutics Inc. is a clinical-stage medical device company pioneering sonic technology to treat cancer in a way that is not only more effective but less invasive for patients. The company's next-generation HIFU therapy system is designed to provide precise, non-invasive, outpatient treatment for solid tumors, beginning with pancreatic cancer.

Sonire Therapeutics Inc. 是一家临床阶段的医疗设备公司，率先利用声波技术治疗癌症，不仅效果更佳，而且对患者的侵入性更小。该公司下一代的高强度聚焦超声 (HIFU) 治疗系统旨在为实体肿瘤提供精准、非侵入性、门诊式的治疗，首先应用于胰腺癌。

Founded in February 2020 in Tokyo and now headquartered in Palo Alto, CA, Sonire is committed to transforming oncology through innovative, patient-centered acoustic engineering. For more information, visit .

Sonire成立于2020年2月，总部位于东京，目前总部设在加利福尼亚州帕洛阿尔托，致力于通过创新的、以患者为中心的声学工程改变肿瘤学。欲了解更多信息，请访问。

www.sonire-therapeutics.com

。

Media Contact

媒体联系人

Ryan Walker

瑞安·沃克

R.J. Walker & Co.

R.J.沃克公司

[email protected]

电子邮件地址

SOURCE Sonire Therapeutics